Oluyemi Okupe Sells 55,383 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 55,383 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $35.09, for a total transaction of $1,943,389.47. Following the transaction, the chief financial officer directly owned 228,938 shares of the company’s stock, valued at $8,033,434.42. This represents a 19.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $31.03 on Thursday. The firm has a market capitalization of $7.24 billion, a P/E ratio of -49.25 and a beta of 2.40. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30. The company’s fifty day moving average is $32.17 and its two-hundred day moving average is $26.05. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the prior year, the business earned $0.17 EPS. The business’s revenue for the quarter was up 38.2% compared to the same quarter last year. Analysts forecast that Hims & Hers Health, Inc. will post -0.05 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HIMS shares. Needham & Company LLC boosted their price target on Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research note on Tuesday, May 12th. TD Cowen lifted their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group upped their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $32.43.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations regarding patient-data sharing, advertising and subscription practices, arguing that the agency misunderstands Hims & Hers’ business model. His comments may have helped ease some investor concerns. Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
• Positive Sentiment: Management continues to highlight growth opportunities, including an AI health coach that could improve medication adherence, expanded patient access and the transition toward branded GLP-1 treatments. These initiatives support the company’s longer-term growth narrative. Hims & Hers CEO discusses AI health coach
• Positive Sentiment: An analyst report described the Eucalyptus transaction as a potential avenue for entering new markets and broadening Hims & Hers’ international reach. Hims & Hers: Eucalyptus Deal Unlocks New Markets
• Neutral Sentiment: Multiple insider dispositions were reported, including sales by the CEO, CFO and other executives. Most involved shares withheld or sold under pre-arranged plans to cover taxes on vested equity awards, making them weaker signals of management’s outlook than discretionary selling. Hims & Hers insider transactions
• Negative Sentiment: The FTC lawsuit remains the central risk, with allegations involving privacy practices, advertising, billing and difficult subscription cancellations. The litigation has also prompted investigations by Kaplan Fox, Berger Montague, Kessler Topaz and other shareholder law firms, raising potential compliance, reputational and securities-liability concerns. Berger Montague investigation
• Negative Sentiment: Although quarterly revenue exceeded expectations and rose strongly year over year, Hims & Hers reported a substantially larger-than-expected loss. Continued questions about profitability and the GLP-1 strategy could limit the stock’s recovery. Questions from the Hims & Hers earnings call

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the third quarter worth about $28,000. Versant Capital Management Inc lifted its stake in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after buying an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares during the last quarter. Silicon Valley Capital Partners acquired a new stake in Hims & Hers Health during the third quarter worth approximately $48,000. Finally, Bogart Wealth LLC grew its stake in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.